| abstract |
A method for evaluating a subject's risk of developing glaucoma, or having glaucoma, or having glaucoma that will progress in severity comprising determining from a biological sample from a subject whether the patient has a mitochondrial haplogroup selected from L2, L2c, L2b, L2alc, L2al'2'3'4 or Llc2, or Llc2blbl. In another embodiment, the method involves determining from a biological sample the occurrence of one or more mutational nucleotide variants in the mtDNA that define a suspect mitochondrial haplogroup. In still another embodiment, the method involves treating the subject having the indicated mitochondrial haplogroup and/or mutational variants with a therapeutic or dietary regimen designed to support mitochondrial function |